The assembly of the genome into chromatin imposes a poorly understood set of rules and constraints on action by regulatory factors. We investigated the role played by chromatin infrastructure in enabling an acute response of the Xenopus TRβA gene to thyroid hormone receptor (TR), an extensively studied member of the nuclear hormone receptor superfamily. We found that in addition to the known TR response element (TRE) in the promoter, full-range regulation required an upstream enhancer that contained multiple nonconsensus TREs and augmented ligand action at high receptor levels. An array of translationally positioned nucleosomes formed over the TRβA locus in vivo; unliganded TR engaged this array in linker DNA between two nucleosomes and via TREs on the surface of histone octamers. Remarkably, assembly of enhancer DNA into mature chromatin potentiated binding by TR to its target response elements and enabled a greater range of regulation by TR than was observed on immature chromatin templates. Because assembly of enhancer DNA into chromatin increased TR binding to the nonconsensus TREs, we hypothesize that chromatin disruption targeted by liganded TR to the enhancer may lead to receptor release from the template and to an attenuation of response to hormone.
Introduction
The study of transcriptional regulation makes extensive use of artificial reporter constructs that contain several binding sites for a particular protein and are introduced into cells by transfection. This useful approach has two limitations: (i) bona fide targets of eukaryotic transcription factors are assembled into chromatin, while nonreplicating episomes are not (1); (ii) the primary sequence of eukaryotic promoters is seldom a reiteration of binding sites for one protein.
With only a few exceptions (2,3), we are far from understanding how the regulatory behavior of a eukaryotic promoter emerges from the union of nonhistone protein binding sites that it contains. In general, naturally occurring promoters studied in their native chromosomal context-e.g., the mouse mammary tumor virus long terminal repeat (MMTV LTR) (4-6), the Drosophila hsp26 gene (7) (8) (9) , and the human pS2 (10, 11) and cathepsin D (12) promoters-offer a far more intricate picture of transcriptional regulation than assays with synthetic reporter constructs placed on nonreplicating episomes (13).
The Xenopus oocyte offers an attractive experimental system for studies of transcription: evolutionarily molded to contain sufficient histone protein and chromatin assembly machinery for several thousand somatic cells, it efficiently assembles microinjected DNA into physiologically spaced chromatin (14) , which offers an excellent opportunity to investigate functional interactions between various regulatory factors and chromatin templates in vivo (15) (16) (17) (18) (19) (20) . The power of this model system is illustrated by data from our laboratory on action by the thyroid hormone receptor (TR); this extensively studied member of the nuclear hormone receptor (NHR) superfamily is exquisitely sensitive to nanomolar quantities of its ligand, thyroid hormone (T 3 ) (21, 22) . TR and T 3 -driven metamorphosis is a central phenomenon in anuran ontogeny (23, 24) , and the frog Our data reveal an upstream enhancer in the TRβA gene locus that contains several unusual TREs and is required for full-range regulation of this gene by T 3 . We describe an array of translationally positioned nucleosomes over the promoter and enhancer in vivo that accomodates at least 4 TR/RXR heterodimer molecules both in linker DNA between adjacent nucleosomes, and on the surface of histone octamers. In contradiction with commonly held notions that chromatin prevents access to DNA by regulatory factors, we show that chromatin assembly potentiates both binding to, and action by TR/RXR on the enhancer. We hypothesize that structural distortion of the DNA assembled into a nucleosomal fiber creates a template that has a higher affinity for TR than naked DNA would be, and suggest that chromatin disruption by liganded TR enables a novel mechanism of attenuating response to hormone by causing receptor release from the template. 
Experimental Procedures
Plasmid constructs for transcription analysis and in vitro mRNA synthesis. Plasmid pTRβA (38) used as a reporter construct contains a fragment of the Xenopus laevis TRβA gene (36) (positions [-1335 ]-[+313] relative to the major transcription start site) subcloned into pBluescript II KS(-). The pTRβA-[∆ site1] construct was generated by replacting the TRE at
[+276] with a unique NsiI recognition site using a combination of published techniques (39) (40) (41) :
pTRβA was denatured with NaOH as described (39) eliminated just the TRE sequences from the TRβA enhancer (data not shown). Clones of TR and RXR were described previously (19, 31) ; these plasmids were linearized with EcoRI and in vitro synthesis of capped mRNA for microinjection was performed with an mMessage Machine kit (Ambion) exactly as described (19) .
Preparation, microinjection, and maintenance of oocytes and primer extension. Oocytes were prepared and injected with mRNA and DNA exactly as described (19, 31) . Total RNA was extracted using RNAzol (Tel-Test; Friendswood, TX) and assayed by primer extension with SuperScript reverse transcriptase (Life Technologies, Gaithersburg, MD) as described (19, 31) .
The reaction contained labelled primers that detected both mRNA synthesized from the reporter construct as well as an RNA stored in the oocyte that served as a loading control during analysis on 6% sequencing urea-PAGE (19, 31) .
Mapping of DNase I hypersensitive sites in chromatin. Oocytes were injected with 5 ng
RXRα mRNA and 5 ng of TR mRNA; following incubation for 10 hrs., 1 ng double-stranded pTRβA DNA was injected. After 16 hrs. of incubation, the oocytes were rinsed in MBSH medium and 20 oocytes per experimental sample were homogenized in 10 mM Hepes pH 7.6, 25 mM KCl, 5 mM MgCl 2 , 5% glycerol, 0.5 mM PMSF, 0.5 mM DTT (42) . The homogenate was placed in a 37°C water bath for 1 min., and DNase I (DPRF grade; Worthington Biochemical, Freehold, NJ) was then added to 110-132 Worthington units/ml. Aliquots of 100 µl were removed from each sample at 1 min. and 3 min. following addition of the enzyme and mixed vigorously with an equal volume of stop buffer (20 mM Tris pH 7.4, 200 mM NaCl, 2 mM EDTA, 2% SDS).
Proteinase K (Roche) was added to 700 µg/ml, and after incubation overnight at 37°C, the DNA was extracted twice with an equal volume of phenol-chloroform-isoamyl alcohol (50:48:2, v:v:v), once with chloroform, precipitated with sodium acetate and 0.7 volumes of isopropanol for 1 hr. on ice, and resuspended in TE buffer. RNA was removed by treatment with 100 µl/ml RNase A (Roche), and the DNA was digested to completion with EcoRI, followed by brief treatment with proteinase K, phenol-chloroform extraction and precipitation with isopropanol as desribed above.
The DNA was resuspended in TE buffer and fractionated (1 oocyte equivalent per sample) on a 2% high-resolution blend (Amresco; Solon, OH) agarose gel in 1x TAE. Southern blotting with random-prime labelled probes was peformed by transferring the DNA to 0.2 µM pore size Nytran Plus nylon membranes (Schleicher and Schuell; Keene, NH), hybridizing, and washing as per the manufacturer's instructions. The final wash was performed in 0.2x SSC, 0.5% SDS, 65°C. In Fig.   1C and 4A, the probe used for Souther blotting hybridized to the 3'-most portion of the TRβA gene construct, and in Fig. 4B -to the 5'-most portion. Filters were exposed to phosphorimager screens or to X-ray film as described above.
Electromobility Shift Assays (EMSA).
Proteins for EMSA were prepared by in vitro translation in a coupled transcription-translation system exactly as described (19) . Equal volumes of reticulocyte lysate contatining TR and RXR were incubated in binding buffer (43) 
Results

The TRβA promoter Contains Multiple In Vivo TR Binding Sites
An outline of the experiment is shown in Fig. 1A : we first microinjected mRNAs for TR and RXR into the oocyte cytoplasm, and following receptor synthesis, injected reporter DNA -
the Xenopus TRβA promoter (36) -into the nucleus. After an incubation period to allow chromatin assembly (14), we measured transcriptional activity of the reporter by primer extension.
Because the oocyte lacks endogenous TR (31), high levels of basal transcription driven by the reporter were insensitive to T 3 in the absence of added TR (Fig. 1B, lanes 3-4) . In contrast, when TR/RXR was introduced into the oocyte, the promoter was very efficiently silenced ( and absence (lanes 8-9) of hormone, indicating that unliganded TR can access its binding sites within unremodeled chromatin. In multiple experiments (data not shown), even in the absence of T 3 we observed three TR-dependent, α-amanitin-insensitive footprints in this area. We therefore conclude that in addition to the previously characterized TRE downstream of the transcription start site (49), the TRβA promoter contains an upstream TR-and T 3 -responsive segment of chromatin that can be bound by TR in vivo via 3 target sites. Futhermore, although we cannot formally exclude the possibility that chromatin structure alterations we describe ( Fig. 1C ) are due to secondary effects of unliganded TR, our data argue very strongly against this notion.
Noncanonical TREs in the TRβA Promoter
The DNA sequence of the upstream stretch of the TRβA promoter bound by TR in vivo Fig. 2A -it contains three matches to a consensus TR response element (22) . We used indirect end-labeling with custom size markers and nucleotide-resolution DNAse I footprinting analysis to confirm that the footprints observed in vivo ( 
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TRE at [-690 ] had a half-site spacing of 3 bp ("DR3"), and the TRE at [-780] -2 bp ("DR2").
The primary sequences of the half-sites diverged from the canonical "AGG(T/A)CA" consensus in precise agreement with in vitro data on TR/RXR binding to DNA (43,50) (see Discussion).
We used an electromobility shift assay (EMSA) to confirm that these DNA sequences can bind TR/RXR. As shown in Fig. 2B , a 25 or 50-fold molar excess of these putative TREs competed with a canonical response element for binding by TR (lanes 5-11). Consistent with their divergence from a 4 bp half-site spacing, elements 2 and 3 bound TR/RXR with lower affinity than element 4 (compare lanes 8-11 with lanes 6-7), or a well-defined TRE from the human genome (lanes 4-5). A "TRE" with point mutations in all DNA residues crucial for binding (50) (lanes 12-13), or a DNA segment of equal length but random sequence (lanes 14-15) both failed to compete for TR/RXR binding (compare to lane 1). We obtained identical results in experiments using all these TREs in labelled form rather than as competitors (data not shown).
We conclude that the putative upstream enhancer of the TRβA gene contains 3 binding sites for TR/RXR, 2 of which have altered half-site spacing relative to a canonical TRE (51) . We show that these unusual TREs can bind TR/RXR in vitro in a sequence-specific manner, albeit with reduced affinity relative to canonical TREs.
The TRβA Enhancer Functions In Vivo to Augment Response to T 3
We used in vivo transcription assays to determine if the putative enhancer has a role in mediating response to T 3 . We hypothesized that its function may be to expand the range of regulation effected by hormone. If that were indeed the case, then a construct containing site 1
( Fig. 2A) These data support our hypothesis that the enhancer contains low affinity in vivo binding sites for TR.
We conclude that the multiple TREs found upstream of the TRβA promoter transcription start site form a bona fide enhancer for TR/RXR action in vivo: we show that the enhancer augments the range of regulation effected by T 3 (Fig. 3A) , and that it can mediate response to T 3 when sufficient quantities of receptor are present in the system (Fig. 3B, lanes 11-14) .
A TR-bound Array of Translationally Positioned Nucleosomes Within the Enhancer
The TREs within the TRβA enhancer diverge from consensus, and yet bind TR in vivo (Fig. 1C ) and respond to T 3 when bound (Fig. 3) . We hypothesized that some feature of in vivo nucleoprotein organization of this DNA stretch potentiates TR action on the enhancer. Three NHR-controlled promoters offer examples of such potentiation: these are GR regulation of the MMTV LTR (4-6), and ER regulation of the pS2 (10,11) and the vitellogenin B1 (52) promoters.
In all these cases, nonranrom histone octamer positions relative to the DNA within the target locus have been implicated in augmenting response to hormone.
We investigated directly whether the TRβA enhancer forms a specific chromatin organization in vivo by using the chemical agent methidiumpropyl-EDTA: it exhibits a marked preference for cleaving linker DNA while displaying negligible primary sequence bias (45, 46, 53) .
In contrast to MPE action on naked DNA, which generated a homogeneous smear (Fig. 4A, lanes   2-3) , chromatin templates exhibited a marked and reproducible nonrandom sensitivity to MPE:
over multiple experiments we consistently found that, even in the absence of TR, pronounced sites of cleavage by MPE spaced by ~180 bp were observed in chromatin (lanes 4-5). In the presence To obtain a more precise estimate of the location of the new TREs we described in the enhancer relative to predominant nucleosome positions, we used custom size markers (4) which migrate at the exact location of the TR footprints (these are prepared by digesting genomic DNA with a restriction enzyme with a cleavage site close to the location of the TRE -see We reproducibly found an area of TR-independent MPE-hypersensitivity immediately upstream of site 2; the resulting stretch of DNA resistant to MPE was ca. 110 bp in length, i.e., less than 1 nucleosome (see stretch of chromatin between EagI and ApaI sites in Fig. 4B , lanes 4-7). We do not understand the structural basis of this nucleoprotein assembly and have provisionally represented the adjacent DNA as a remodelled nucleosome (dotted ellipse): it is possible that factors endogenous to the oocyte exert some unilateral (i.e., from the upstream side only) disruption of histone-DNA contacts in the area.
Our data on nucleosome and TRE position in the area are summarized in Fig. 4C : we show that nucleosomes in this area exhibit a nonrandom distribution relative to the DNA, and that the TRβA enhancer is assembled into 3 translationally positioned nucleosomes, with 2 molecules of TR/RXR bound to linker DNA, and a 3 rd molecule occupying the surface of a nucleosome-like particle.
TR Binding and Action on the TRβA Enhancer is Potentiated by Chromatin Assembly
The nonrandom chromatin infrastructure over the enhancer (Fig. 4) suggested that its dynamic assembly might affect the ability of TR/RXR to act via this stretch of DNA. The Xenopus oocyte offers a unique opportunity to investigate this issue directly: the assembly of microinjected double-stranded DNA into chromatin occurs gradually over the course of several hours (14) . For example, as shown in Fig. 5B, 1 hr. after injection into the oocyte nucleus, pTRβA DNA is highly sensitive to MNase and nucleosomal density is low (lanes 2-3); after 3 hrs., nucleosome density increases, but the bulk of the signal derives from mono-and di-nucleosomal particles, and signal from a "seminucleosome" ("0.5n")-a chromatin assembly intermediate (56, 57) -is conspicuous.
By later timepoints (lanes 11-12), chromatin assumes a more mature configuration, and signal from assembly intermediates is undetectable.
This interesting property of the oocyte-i.e., a kinetics of chromatin assembly that is markedly delayed relative to the 30 min. replication-coupled pathway (58)-allows for the experimental arrangement shown in Fig. 5A : oocytes are injected with mRNA and incubated for a set length of time to allow receptor synthesis. DNA is then injected and oocytes are cultured in the presence or absence of T 3 ; groups of oocytes are removed at specific timepoints following DNA injection, and transcription is measured (or chromatin structure is assayed -see below).
Thus, the regulatory competence of TR/RXR can be examined on templates that are in various states of chromatin assembly.
In such experiments, we reproducibly found that the full-length TRβA promoter was regulated by T 3 with equal efficiency at all states of template chromatinization (Fig. 5D , compare lanes 1-3 with lanes 7-9). In contrast, a construct that contained only the TRβA enhancer (i.e., no site 1) was robustly responsive to TR when DNA was fully chromatinized (lanes 10-12), but impaired in response to hormone at early timepoints (lanes 4-6), when DNA is in immature, partly assembled chromatin (Fig. 5B, lanes 2-3 and 5-6 ). We reproducibly found that at early timepoints following DNA injection, the reproducibly observed lower transcriptional activation by liganded TR on the [∆ site 1] construct as compared to the wild-type promoter (Fig. 5D , compare lanes 4 and 6 with lanes 1 and 3).
The data shown in Fig. 5D had a trivial explanation: we had earlier shown that the [∆ site 1] construct is impaired in responding to TR and T 3 at low TR levels (Fig. 3B, lanes 8-10) .
It was possible that the difference we saw in TR action on the two reporter constructs (Fig. 5D , lanes 1-3 vs. lanes 4-6) was due to low TR levels at the early timepoint (lanes 1-6) and an increase by the late timepoint (lanes 7-12). To address this issue, we examined the TR content of the oocyte during the course of the experiment by Western blotting (Fig. 5C) ; the antibody used recognized a ~240 kDa polypeptide ("?" in Fig. 5C ) in oocytes that were not injected with TR mRNA (Fig. 5C, lane 1) , which served as a loading control. Such analysis showed that TR levels did not change in the oocyte over the course of the experiment ( We conclude that action of TR/RXR on the enhancer element we have described is potentiated by assembly of the target DNA into chromatin (Fig. 5D ). We show that the capacity of unliganded TR to bind the unusual TREs in the TRβA enhancer is regulated by the extent of template chromatinization, such that more mature chromatin templates are bound to a greater extent than those in the process of assembly (Fig. 5E) . Importantly, this change in the functional properties of TR (Fig. 5D ) and in its ability to bind the enhancer (Fig. 5E ) occurs without any detectable alteration of TR protein levels (Fig. 5C ). 
Discussion
The thyroid hormone receptor can regulate transcription in vitro on naked DNA templates, i.e., in the absence of any chromatin (59, 60) . In the nucleus, however, the receptor establishes a poorly understood functional relationship with the chromatin infrastructure of its target promoters (21, 22) . The present study describes a positive role for a structurally mature chromatin template in allowing maximal response to TR and T 3 : we show that a naturally occurring TR-regulated gene contains an upstream enhancer bound into an array of translationally positioned nucleosomes in vivo (Fig. 4) , and demonstrate that this nucleoprotein entity potentiates binding by TR/RXR to multiple nonconsensus TREs located in the enhancer (Fig. 1C, 2A , and 5E), thereby expanding the range of regulation effected by the liganded NHR ( Fig. 3A and 5D ).
To the best of our knowledge, these are the first data in the literature that a non-viral NHR target gene presents itself to the receptor in the form of a specifically structured chromatin template that is required for full-range regulation by hormone.
The previously described (49) TR binding site in the TRβA promoter ("site 1" at [+276])
is sufficient to make it responsive to T 3 (Fig. 3A) . We found, however, that its action cannot account for the entirety of T 3 response (Fig. 3) , and present evidence that additional regulation is imparted by a segment of DNA located at positions [-800]-[-500]. This element fits several criteria for an enhancer: it is bound by TR in vivo (Fig. 1C) , it contains 3 sequence elements that can be bound by TR in vitro (Fig. 2B) , it is sufficient to enable response to TR (Fig. 3B) , and allows liganded TR to drive higher levels of transcription than can be achieved via a single TRE (Fig. 3A) . Our data agree with findings of an earlier study (61) , in which EMSA and transient transfection assays suggested the existence of TR-responsive elements upstream of the TRβA transcription start site.
Our footprinting (Fig. 1C) , EMSA (Fig. 2B) , and functional (Fig. 3A) (Fig. 1C) , while exhibiting only a moderate reduction in affinity in vitro (Fig. 2B) . The 1.9 kb TRβA promoter fragment contains ca. 20 sequences that are partial (mismatch=3 nt) matches to the TRE "consensus" (data not shown), but only 3 are bound by TR in vivo (Fig. 1C) ; comparison of the remaining 17 to data presented by Judelson and Privalsky (50) indicates that the mismatches would be expected to significantly impair receptor binding. Our in vivo data thus fully support the notion that TR exhibits a restricted, rule-based promiscuity in DNA binding.
Our data indicate that binding and action by TR on the enhancer are potentiated by chromatin assembly (Fig. 5) , a surprising finding considering that nucleosomes impede binding to DNA by most nonhistone factors (66, 67) with only a few exceptions (65) . In the promoter we study, the translational frame of nucleosome occupancy is receptor-independent ( 4C). It is possible, therefore, that the spatial proximity of DNA entering and exiting the histone core creates a "static loop" (7, 8, 10, 11, 52) that enables an interaction between two TR/RXR heterodimers. It is also possible that the unwinding and distortion of the DNA helix complexed with histones (68) potentiates binding by TR/RXR to site 2 (a motif of two direct repeats spaced by 2 bp) by increasing the distance between the two half-sites to a level more compatible with heterodimerization on the DNA of the two NHRs (which normally require a 4 bp spacer (51)).
Naturally occurring promoters frequently contain multiple binding sites for a particular regulator (69, 70) , and many NHR-responsive genes are controlled via arrays of receptor response elements: for example, the MMTV LTR contains at least 6 GREs (71), and the AR-regulated prostate-specific antigen enhancer includes 4 AREs (72). Such promoter structure is thought to enable a sigmoidal response curve to a rise in regulator titer (69, 70, 73, 74) . The TRβA promoter conforms to this paradigm, having evolved under selective pressure to coordinate ligand and receptor levels and allow for autoregulation by hormone of the titer for its own receptor during metamorphosis (75,76). In addition, our data illuminate a novel role for chromatin assembly and primary promoter sequence in a general phenomenon: enabling a correlation between between titers of a given NHR and its cognate ligand (76) , which has been observed for GR (77) (78) (79) , ER (80) , AR (81, 82) , EcR (83) , and RAR (84).
Early in development, when TR levels are low, regulation of the TRβA gene likely occurs via the "site 1" TRE, which has the highest affinity for TR -this is sufficient for repression ( Fig.   3A ) and moderate activation (Fig. 3B) . As hormone and receptor titers rise during ontogeny, binding by TR to the lower-affinity enhancer TREs (Fig. 2B ) is predicted to lead to graded transcriptional activation above basal levels ( Fig. 3A and 3B) . autoregulatory loop between T 3 and TR: the placement of lower-affinity TREs in the enhancer ensures that it begins to function only when TR titer is sufficiently high.
An important component of an autoregulatory circuit is the attenuation of response to signal, which, in the case of TR and T 3 , is partly effected by proteolysis of liganded TR (19, 85) .
We suggest that the unique structure of the TRβA enhancer may also contribute to such attenuation: binding by unliganded TR/RXR to the enhancer is potentiated by assembly of the DNA into a mature array of translationally positioned nucleosomes (Fig. 5E) , and liganded TR disrupts this array ( Fig. 1C and 5A ), thereby creating a lower affinity template for itself. Thus, TR-targeted chromatin disruption may lead to receptor release from the enhancer and a lowering of transcription initiation rates (Fig. 3A) . In vivo, non-NHR transcriptional regulators such as
Swi5p (86), and such NHRs as GR (71, 87) and ER (12), bind chromatin only transiently, and it is quite possible, although unproven, that the large ATP-dependent chromatin remodeling complexes they target are partly responsible for such "hit-and-run" action. In our model system this issue can be studied with in vitro assembled chromatin templates that have been shown to recapitulate certain aspects of gene regulation by NHRs (71, 88, 89) . 
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31. (even-and odd-numbered lanes, respectively) of the indicated unlabelled double-stranded oligonucleotide was included in the reaction. The "meTRE" competitor represents the wellcharacterized TRE from the malic enzyme promoter (44), the "mut. TRE" is an oligonucleotide of identical length with point mutations in residues critical for binding by TR/RXR (50), and "nonsp." is an oligonucleotide of identical length of random sequence. The reaction mixes were resolved by EMSA and the "bound" and "free" bands quantitated via Phosphorimager analysis.
Figure Legends
To quantify relative competitor potency, the intensity of the shifted band ("TR/RXR-DNA")
derived from receptor binding in the absence of competitor (lane 1) was set to 100% and the signal obtained in the presence of the various competitors was expressed as a fraction thereof (shown below each lane as "% bound"). Following culture in the presence or absence of T 3 , transcriptional activity of the TRβA promoter was measured as described in Fig. 1 . A summary of data from 4 independent experiments is shown in the graph on the bottom (the S.E.M. for lane 12 is 2.45). by guest on October 5, 2017
